• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Climb Bio Inc.

    4/25/25 4:02:59 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    DEFA14A 1 d935430ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    CLIMB BIO, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    Climb BioYour vote matters!PROXY TABULATOR P.O. 8016, CARY, NC 27512-9903Climb Bio, Inc.Annual Meeting of StockholdersWednesday, June 4, 2025 9:00 AM, Eastern TimeAnnual Meeting to be held exclusively via the Internet - please visit www.proxydocs.com/CLYM for more details.You must register to attend the meeting online and/or participate at www.proxydocs.com/CLYMFor a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/CLYMTo vote your proxy while visiting this site, you will need the 12 digit control number in the box below.This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.If you want to receive a paper or email copy of the proxy materials, you must request one on or before May 23, 2025. There is no charge to you for requesting a copy. Unless requested, you will not otherwise receive a paper or email copy.Proxy Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-KImportant Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held on June 4, 2025 For Stockholders of Record as of April 7, 2025To request paper copies of the proxy materials, use one of the following methods.* If requesting a copy of the proxy materials by email, please send a blank email with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your email requesting a copy of the proxy materials.Your control numberHave the 12 digit control number located in thebox above available when you access thewebsite and follow the instructions.SEE REVERSE FOR FULL AGENDACopyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    Climb Bio, Inc. Annual Meeting of StockholdersFOR EACH OF THE DIRECTOR NOMINEES IN PROPOSAL 1 AND FOR PROPOSAL 2.PROPOSALThe election of two directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified:Judith Dunn, Ph.D.Stephen Thomas, Ph.D.The ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.Note: The transaction of any other business that may properly come before the 2025 annual meeting of stockholders or any adjournment or postponement thereof.

    Get the next $CLYM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    10/16/2025Outperform
    William Blair
    10/13/2025$9.00Buy
    H.C. Wainwright
    8/15/2025$9.00Outperform
    Robert W. Baird
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Climb Bio

    William Blair initiated coverage of Climb Bio with a rating of Outperform

    10/16/25 8:22:17 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Climb Bio with a new price target

    H.C. Wainwright initiated coverage of Climb Bio with a rating of Buy and set a new price target of $9.00

    10/13/25 8:52:19 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Climb Bio with a new price target

    Robert W. Baird initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $9.00

    8/15/25 8:18:48 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Business Officer Wilson Perrin Megan

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/8/26 4:05:13 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Brennan Aoife

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/8/26 4:05:18 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Senior Vice President, Finance Driscoll Cindy

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/8/26 4:05:05 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    SEC Filings

    View All

    Climb Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    1/8/26 7:07:49 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Climb Bio Inc.

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    12/31/25 4:12:49 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Climb Bio Inc.

    SCHEDULE 13D/A - Climb Bio, Inc. (0001768446) (Subject)

    12/15/25 7:56:05 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Climb Bio to Present at Upcoming Investor Conferences

    WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Guggenheim's Emerging Outlook: Biotech SummitFormat: Fireside ChatDate: Thursday, February 12, 2026Time: 3:00 – 3:25 p.m. ET Oppenheimer 36th Annual Healthcare Life Sciences Conference Format: Fireside ChatDate: Wednesday, February 25, 2026Time: 1:20 – 1:50 p.m. ET Leerink Global Healthcare Conference Format: Fireside ChatDate: Monday, March 9, 2026Time: 2:20 – 2:50 p.m. ET The live

    2/5/26 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

    First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced progress upd

    1/8/26 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio's 2025 Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Climb Bio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on November 24, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of Climb Bio, which

    11/25/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $24,888 worth of shares (7,111 units at $3.50) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/7/26 4:55:47 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. returned 20,440,000 shares to the company and bought $754,737 worth of shares (314,561 units at $2.40) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    12/15/25 7:55:04 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

    WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. "Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team," said Aoife Brennan, President and CEO of Climb Bio. "Our company is making excellent progress advanci

    10/1/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

    Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

    6/18/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

    SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

    11/14/24 9:29:34 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care